Table 2 Immunosuppressive treatment
Avacopan (n = 21) | |
|---|---|
Time to start avacopan, days | 12 (5–26) |
Duration of avacopan use, months | 13 (2–13) |
Induction therapy | |
Rituximab | 16 (76.2%) |
Single dose of rituximab | 15 (71.4%) |
Two doses of rituximab | 1 (4.8%) |
Azathioprine | 3 (14.3%) |
Glucocorticoid monotherapy | 2 (9.5%) |
Use of methylprednisolone pulse therapy | 6 (28.6%) |
Maintenance therapy | |
Rituximab | 15 (71.4%) |
Azathioprine | 3 (14.3%) |
Mizoribine | 1 (4.8%) |
Prednisone dose | |
Initial dose, mg/day | 40 (28–43) |
Dose at 1 month, mg/day | 8 (5–14) |
Dose at 3 months, mg/day | 4 (1–5) |
Dose at 6 months, mg/day | 2 (0–5) |
Dose at 12 months, mg/day | 0 (0–2) |
Cumulative dose at 1 month, g | 0.5 (0.3–0.6) |
Cumulative dose at 3 months, g | 0.6 (0.5–0.8) |
Cumulative dose at 6 months, g | 0.9 (0.8–1.3) |
Cumulative dose at 12 months, g | 1.0 (0.9–1.4) |
Off prednisone at 6 months | 8 (38.1%) |
Off prednisone at 12 months | 10 (47.6%) |